Massive IPO Stock Alert: Lucy Scientific (NASDAQ:LSDI) Announces It’s $7.5M IPO
Lucy Scientific manufactures therapeutic psychedelics and made a huge announcement, we will get to that soon.
The Global Psychedelics Market Is Expected To Reach almost $100 BN By 2029 Full Article
That is larger than the cannabis market segment, without a market leader.
Lucy Scientific has made some serious steps toward possibly dominating the market.
This is exciting investors, it is a second chance at the cannabis boom but bigger.
In case, you need a reminder of how crazy that ride was, the market grew by 250% in less than a year.
UPDATE:
Breaking News:
March 21, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company, announced that it has entered into a definitive asset purchase agreement with Wesana Health Holdings Inc. (“Wesana”).
Lucy has agreed to acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, and Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies. The aggregate consideration comprises 1,000,000 shares of common stock and $570,000 in cash. The shares will be subject to a lock-up agreement whereby half of the shares will be released 9 months from closing, and other half will be released 14 months from closing. The transaction is also subject to Wesana’s shareholder approval and is expected to close in Q2 2023.
Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential, concentrating on IPOs and we have uncovered some interesting data on LSDI.
Our research reports have uncovered some of the largest breakout stock alerts year after year.
LSDI may even be the best yet. So put us to the test and put it on your watchlist.
We stand by our alerts, our 2023 alert tracker provides transparency. Click HERE
Small Cap Exclusive’s much anticipated research report on Lucy Scientific (NASDAQ:LSDI) is found below.
Top 3 catalysts that could send LSDI up 127%++ in the next month:
#1 The Chart
#2 IPOs Offer A Significant Upside Potential
#3 The Market Could Be As Big As Coffee
Lucy’s Other Explosive Catalysts
- Recent news has has not been covered by major financial news outlets, creating a unique opportunity.
- Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin. Press Release
- Files Amendment with Health Canada to Expand its List of Controlled Substances to Include Cocaine and Heroin Press Release
Why do we consider Lucy Scientific as a contender for the best stock of 2023?
Large announcements in the drug world is turning heads on Wall Street and it feels like 2017’s green boom with cannabis.
Wait until you see what we have uncovered!
Major Psychedelic Announcements:
2019: May 9th
Denver, Colorado became the first city in the United States to decriminalize the cultivation, possession and use of psilocybin mushrooms.
2019: June 5th
Oakland California decriminalized the cultivation, possession and use of plants or fungi containing psychedelic compounds including DMT, ibogaine, mescaline and psilocybin.
2019: September 4th
Johns Hopkins launched the Center for Psychedelic and Consciousness Research. The center’s director, Roland Griffiths, said that researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, learning, memory, and biological markers of health.
2019: November 22nd
The Food and Drug Administration granted Breakthrough Therapy designation to the Usona Institute for its psilocybin therapy for major depressive disorder. Usona’s phase 2 clinical trials will include 80 volunteers at seven sites around the U.S.
2020: October 22nd
In Vancouver, Canada Numinus Wellness Inc. harvested the first legal flush of psilocybin mushrooms by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s License.
2021: October 18th
Johns Hopkins Medicine was awarded a $3.9 million grant by the National Institutes of Health (NIH) for clinical research on psilocybin-assisted psychotherapy to treat tobacco addiction.
Let’s take a closer look at Lucy LSDI.
2023: March 23
Announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.
The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.
Lucy Scientific Discovery Company Summary
Company Name: Lucy Scientific Discovery
Ticker: LSDI
Exchange: NASDAQ
Website: https://www.lucyscientific.com/
Lucy’s Company Summary:
Lucy Scientific Discovery Inc. [NASDAQ:LSDI] an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry.
Lucy maintains a Controlled Drugs and Substances Dealer’s License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer’s License, that was issued to Lucy by Health Canada’s Office of Controlled Substances.
This Dealer’s License authorizes the Company to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.
Before we review #1 Catalyst, their technology suite, let’s review how the catalysts above could generate parabolic growth.
As mentioned above, Lucy Scientific Discovery trades on the NASDAQ as an IPO, which indicates the incredible upside potential.
#1 The Chart
The chart has clearly broken out and is creating a bullish trend line. Start your research now before it is too late, just like the green boom.
#2 IPOs Offer A Significant Upside Potential
Facebook META acted the same way as most IPOs with hype. They get overbought, they pull back and then run like mad!
Lucy is following that same pattern and we believe it has created a bottom and has broken out clearly in the above image.
Look at what Motley Fool wrote about the massive opportunity FB provided, “The stock was offered at $38 per share via the IPO. Let’s assume you bought 132 shares for a total of $5,016 on May 18, 2012, and held all the way through to today. At today’s price of around $191 per share, those 132 shares would be worth $25,212, resulting in a market-beating five-bagger.”
Just like the cannabis boom, and Facebooks IPO, traders are being handed another possible monumental opportunity.
#3 The Market Could Be As Big As Coffee
The global mushroom market size was valued at USD 50.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2022 to 2030. The increasing vegan population demanding a protein-rich diet around the globe is expected to be a key driver for the market over the forecast period. Mushrooms are considered a superfood owing to their nutritional contents. Mushrooms are packed with four key nutrients namely selenium, vitamin D, glutathione, and ergothioneine. These nutrients help mitigate oxidative stress and prevent or decrease the risk of chronic conditions such as cancer, heart disease, and dementia. Moreover, it offers a strong natural umami flavor, allowing consumers to reduce salt proportion in mushroom meals by 30-40%, thereby benefitting health.
The U.S. was the second-largest producer accounting for approximately 375 million kg in the year 2019. The production in the country is declining since 2017 and has declined by 11% from 2017 to 2019. Whereas the demand from end-users is growing, which has resulted in an increase in the prices by 6% in 2017-18 and by 3% in 2018-19. The U.S. government is continuously increasing import duties, which is also contributing to the higher prices of mushrooms. Mushroom is one of the protein-rich vegan sources as it offers nearly 3.3 g of protein per 100 g of serving. Meat has been a key source of protein in the western diet; thus, the population adopting a vegan diet is anticipated to prefer protein-rich vegan products to fulfill their daily protein requirements.
Condensed Disclaimer
Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $350,000 from Lucy Scientific Discovery Inc. for profiling LSDI. We own ZERO shares in LSDI.
FSD Pharma Inc. (HUGE) Is Bullish On ALL 19 Technical Indicators
FSD Pharma Inc. HUGE stock could be heading to the moon, look at this chart below!
Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:
#1 All Technical Indicators & The Chart Are BULLISH
#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis
#3 The Stock Has A History Of Big MOVES
FSD Pharma Growing Systems Company Summary
Company Name: FSD Pharma Inc.
Ticker: HUGE
Exchange: NASDAQ
Website: https://fsdpharma.com/
Company Summary: FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
No need to really discuss this in great detail, this is incredibly rare to have all 19 technical indicators on Yahoo and Market Watch agreeing that this stock is BULLISH.
There are no Guarantees in the stock market BUT this is as close as we have ever seen!
Seeking Alpha wrote an amazing article on FSD Pharma Inc. (NASDAQ:HUGE) and we include an excerpt from it below.
- “The shares of Canadian biotech FSD Pharma (NASDAQ:HUGE) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302.
- Issuing a No Objection Letter (NOL), Health Canada has granted the regulatory nod to start the first-in-human clinical trial for LUCID-21-302 in the country, FSD (HUGE) said without detailing the estimated timeline for the study.
- “We will continue to work with Health Canada and other regulators worldwide to complete clinical investigations as soon as we can,” Chief Executive Lakshmi Kotra remarked.
- Preclinical studies have indicated the potential of LUCID-21-302 in the prevention of myelin degradation, which is believed to result in neurogenerative diseases such as MS, where there is damage to the myelin sheath in neuronal cells.
- The Toronto-based pharma announced in September that the US and Canadian regulators cleared its mid-stage trial for FSD201 to treat a form of pain caused by the abnormal functioning of the body’s mast cells called idiopathic mast cell activation (IMCA) syndrome.“
Press Release Below
February 7th 2023
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announces the receipt of a No Objection Letter (“NOL”) from Health Canada regarding the Company’s proposed Phase 1 clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of Multiple Sclerosis (“MS”). The NOL provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.
Look at this BEAST, exploding from $1.36 to $4.09 representing 200% gains!
WOW, $17 to $154 representing almost 1,000% gains. Furthermore, the fact that it was at $154 pre-covid and supply chain difficulties reveals the MASSIVE potential of this burgeoning Wall Street darling!
Let’s recap!
Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:
#1 All Technical Indicators & The Chart Are BULLISH
#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis
#3 The Stock Has A History Of Big MOVES
Happy Trading!
DISCLAIMER
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling HUGE. We own ZERO shares in HUGE.
Friday Feb 3rd, All eyes on MDJH our low float momentum play!
Pull up MDJH now, super low float momentum play for Friday, tomorrow, Feb 3rd.
The float is super low at 1.4M shares!
This stock has a history of 100% gains with very low volume.
MDJH should be very active in the morning, so be ready!
The definition of a momentum play is:
when you buy a stock because the stock is moving big and you are hoping to scalp a quick gain if the move continues.
We think this is going to be “moving big” at the morning bell.
Remember, this stock moves very fast on a few trades.
So be ready tomorrow morning!
We have identified 2 catalysts revealing the hidden potential with MDJH.
Before we go over the catalysts, let’s do a quick summary on MDJM Ltd (NASDAQ: MDJH)
MDJM Ltd Company Summary
Company Name: MDJM Ltd
Ticker: MDJH
Exchange: NASDAQ
Website: http://ir.mdjmjh.com/
MDJM Ltd Growing Systems Company Summary:
Founded in 2002 and headquartered in Tianjin, China, Mingda Tianjin is an emerging, integrated real estate services company in China.
We primarily provide primary real estate agency services to our real estate developer clients, and provide, on an as-needed basis, real estate consulting services, and independent training services.
MDJH Has Two Catalysts That Could Send It To The Moon Tomorrow
#1 Low Float
#2 Small amount of volume makes it explode
LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!
Stock MDJH has ONLY 1.4M shares in the float.
Our last two alerts traded 1M shares each, that would almost be the WHOLE FLOAT!
Our subscribers have an amazing opportunity!
What do we mean by, “our subscribers have an amazing opportunity!”?
We love low float stocks because of their ability to MOVE.
They provide great upside opportunities for day traders.
What is a “low float stock”?
Low float stocks are those with a low number of shares. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm’s total outstanding shares. Closely-held shares are those owned by insiders, major shareholders, and employees.
MDJH has only 1.4M shares in the float.
While the average NASDAQ float we normally feature is 10M shares, 10X higher!
This stock has very little supply of shares in the market and our subscribers normally create a large amount of demand.
Remember, LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!
On August 2nd of last year MDJH traded around our average volume of 1.7M shares and went up almost 100%!
That day went like this, someone invested $10,000 and had $20,000 in just a few hours.
Again, our average alerts trade 1-2M shares
The last time MDJH had that kind of volume was in August and went up almost 100%!
Let’s Recap The Two Catalysts That Could Send It To The Moon Tomorrow
#1 Low Float
#2 Small amount of volume makes it explode
Disclaimer
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling MDJH. We own ZERO shares in MDJH.
Best Stocks of 2023: Buy Ratings for GoldMining (NYSE: GLDG)
Why is GoldMining (NYSE: GLDG) a strong buy target by these 3 analysts and could it be one of the best stocks of 2023? link
But before we get started, take a look at our last alerts, we are crushing the STREET!
We have 3 catalysts that have catapulted GLDG into the spotlight.
#1 The news is driving massive volume spikes!
#2 The chart is absolutely perfect and could be ready for a monster run.
#3 So many industry authorities issued a a “Buy Rating”
First and foremost, January’s news release is dynamite!
GoldMining Triples Gold Equivalent Inferred Resource Estimate To 1.45Mn Ounces At La Mina Project With La Garrucha Discovery
La Garrucha deposit adds approx. 1.0 million oz AuEq in the Inferred category and 0.2 million oz AuEq in the Indicated category
Updated Mineral Resource estimate inclusive of La Garrucha positions La Mina with 1.15 million oz AuEq Indicated and 1.45 million oz AuEq Inferred resources
The press release reads:
Jan. 23, 2023
Announced an updated Mineral Resource estimate (“MRE”) on its 100% owned La Mina Project located in Colombia.
The MRE includes a maiden resource estimate on the La Garrucha deposit which incorporates drilling completed by 2023.
Alastair Still, CEO of GoldMining, commented, “We are extremely pleased that the Company’s first exploration drilling program at La Mina has identified a significant discovery!”
“This exciting discovery has exceeded our expectations!”
Tim Smith, Vice President, commented, “The updated Mineral Resource estimate at La Garrucha represents an unqualified success for the Company!”
Take a look at this chart!
The next run will test the 3 month high based on technicals.
This should break through based on the technical indicators below:
Barchart was reporting these as triggered:
Short Term Indicators
- 20 – 50 Day MACD Oscillator
- 20 – 100 Day MACD Oscillator
- 20 – 200 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 – 100 Day MACD Oscillator
- 50 – 150 Day MACD Oscillator
- 50-200 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
The website also shares its all-important “Trend Seeker” composite indicator is triggered.
Watch these technicals closely this week.
TipRanks Reported $5.25 Target Provides Over 320+% Potential Upside
GLDG is displaying a ton of potential upside to this $5.25 target.
In fact, that’s 320+% potential upside.
Now, I’m not saying this profile is going to surge to $5.25 this week, but the potential upside needs to be noted.
Plus, don’t forget, GLDG has a 52-week high over $2.00 which may also help signal that this NYSE American profile could be undervalued from current levels.
Also, GoldMining (NYSE: GLDG) has yet another strong buy target by these 3 analysts and could it be one of the best stocks of 2023? link
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $7,500 from East Coast Media, LLC for profiling GLDG. We own ZERO shares in GLDG.
Best Stocks of 2023 Best NASDAQ Stocks, delivered to YOU
Delivering the best NASDAQ stocks of 2023 yielding on average double digit gains.
We believe in transparency!
We post every pick so you can feel confident in our 💎 featured breakout alerts.
Small Cap Exclusive’s Best NASDAQ Stocks of 2023:
Best Stock of 2023 Avalon GloboCare Corp. (ALBT)
Ticker: ALBT
Corp Name: Avalon GloboCare Corp.
Date Of Alert: March 6th
Alert Price: $2.14
Date Of High: March 6th
High After Alert: $3.87
Gain/Loss: Gain of 81%
Best Stock of 2023 Mainz Biomed (MYNZ
Ticker: MYNZ
Corp Name: Mainz Biomed
Date Of Alert: February 15th
Alert Price: $7.35
Date Of High: February 15th
High After Alert: $7.50
Gain/Loss: Gain of 17%
Best Stock of 2023 FSD Pharma Inc. (HUGE)
Ticker: HUGE
Corp Name: FSD Pharma Inc.
Date Of Alert: February 9th
Alert Price: $1.44
Date Of High: February 11th
High After Alert: $1.68 (52 Week High)
Gain/Loss: Gain of 17%
Best Stock of 2023 MDJM Ltd (MDJH)
Ticker: MDJH
Corp Name: MDJM Ltd
Date Of Alert: February 3rd
Alert Price: $1.80
Date Of High: February 3rd
High After Alert: $2.10
Gain/Loss: Gain of 17%
Best Stock of 2023 Uranium Royalty Corp. (UROY)
Ticker: UROY
Corp Name: Uranium Royalty Corp.
Date Of Alert: February 1
Alert Price: $2.80
Date Of High: February 1st
High After Alert: $2.93
Gain/Loss: Gain of 5%
Best Stock of 2023 Stock GoldMining Inc. (GLDG)
Ticker: GLDG
Corp Name: GoldMining Inc.
Date Of Alert: January 31st
Alert Price: $1.15
Date Of High: February 1st
High After Alert: $1.24
Gain/Loss: Gain of 7%
Best Stock of 2023 Stock Avalon GloboCare Corp. ALBT
Ticker: ALBT
Corp Name: Avalon GloboCare Corp
Date Of Alert: January 8th
Alert Price: $4.01
Date Of High: January 9th
High After Alert: $4.47
Gain/Loss: Gain of 11%
Best Stock of 2023 Stock Clearmind Medicine Inc. CMND
Ticker: CMND
Corp Name: Clearmind Medicine Inc.
Date Of Alert: January 4th
Alert Price: $3.26
Date Of High: January 9th
High After Alert: $5.10
Gain/Loss: Gain of 56%
Best NASDAQ Stock Kaival Brands Innovations Group, Inc. (KAVL)
Ticker: KAVL
Corp Name: Kaival Brands Innovations Group, Inc.
Date Of Alert: December 6th
Alert Price: $.98
Date Of High: December 8th
High After Alert: $1.10
Gain/Loss: Gain of 11%
Best NASDAQ Stock LuxUrban Hotels Inc. (LUXH)
Ticker: LUXH
Corp Name: Kaival Brands Innovations Group, Inc.
Date Of Alert: November 30th
Alert Price: $1.40
Date Of High: January 11th
High After Alert: $1.80
Gain/Loss: Gain of 28%
Our commitment to delivering the best stocks of 2023:
Facebook LINK
How do we deliver the best stocks of 2023?
Fast & Actionable Alert Delivery
As soon as a potential trade presents itself, our team works to send out the trade alert quickly, delivering high quality alerts for traders and investors.
Unlock Your Best Trading Potential
The best NASDAQ Stocks are more accessible than ever before. Get started with just a smart phone in your hand, use the tools we provide to enhance your trading level.
Top Picks From Curated Watchlists
We spend our time scanning the market and analyzing our watchlists looking for the best trade ideas to alert our members. Our team does this so you don’t have to!
Partial Disclaimer
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $5,000 by Life water Media on Jan 9 for ALBT, $5,000 from Life Water Media for profiling CMND, KAVL on Dec 6 paid $8,000 by Awareness Consulting. LUXH – Nov 30 – not compensated. We own ZERO shares in any above mentioned stock.
We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign.
Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!
With An Accelerated Near-Term Path For Product Commercialization And Expanded Manufacturing Capacity, Sharps Technology, Inc. (NASDAQ: STSS) Will Have The Ability To Support The Industry With Innovative, Market Leading Injectable Drug Delivery Solutions And Accelerate A Path Towards Revenue Growth.
Newly NASDAQ-traded Sharps Technology, Inc. (NASDAQ: STSS) offers innovative injectable syringe solutions to a global healthcare crisis that is not being talked about nearly enough.
- Most syringes waste a significant amount of injectable medicine which is thrown away with the used needle/syringe.
- This adds cost and reduces the availability of life-saving injectable drugs for us all. Whether we are looking at a pandemic response, hard-to-manufacture drug products, or managing long-term chronic illness, we can’t afford to waste this precious supply.
- The problem is sufficiently worrisome that the Federal Government is passing new legislation (January 1, 2023) requiring pharmaceutical companies to pay financial penalties for injectable drugs which are thrown away with the syringe and not injected into the patient.
Sharps Technology Company Summary
Company Name: Sharps Technology, Inc.
Ticker: STSS
Exchange: NASDAQ
Website: www.sharpstechnology.com
Sharps Technology Company Summary:
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.
The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features.
These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use.
Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing.
The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Sharps Technology has agreed to manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.
Jan. 10, 2023
Announces the advancement of the Company’s specialized prefillable syringe (“PFS”) system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.
Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems.
These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors.
The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market.”
Sharps Technology commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.
Dec. 20, 2022
Announced they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.
The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.
Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry.
These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention.
By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments.
Sharps Technology signed of a distribution agreement with partner Nephron Pharmaceuticals
Dec. 13, 2022
Announced the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.
“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”
- Each year almost 20 billion injections are administered, globally and the World Health Organization (WHO) are advocating for the use of low waste syringes, with passive safety devices which engage automatically and have auto disable features.
- STSS anticipates signing its first product orders any moment now this development will represent a huge milestone for this recently debuted NASDAQ company, and should provide them with a solid foundation for growth.
- The company has raised $16M to scale operations in the coming quarters as they begin to meet the strong and growing demand for smart safety syringes
The global vaccines market is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028.
Vaccines are the most powerful and cost-effective way to protect billions of people in the world, and according to the WHO, immunization awareness and government initiatives have helped prevent 2-3 million deaths a year.
The Covid-19 outbreak led to a shutdown of syringe manufacturing which in turn led to a supply shortage at a global scale.
Mergers and acquisitions of companies such as STSS are highly attractive and are providing the needed innovation to the vaccine market.
The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes.
Specialty Syringes – Vial Application
- Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR
- Types: Auto-Disable Syringes and Safety Syringes
- Applications: Vaccination and Drug Delivery
- End Users: Hospitals, HMOs and Clinics
- Target Markets: North America, Europe, and ROW
- Sharps Technology listed as a supplier
The Pre-Filled Syringe (PFS)/Ready- To- Fill (RTF) syringe product segment will be a priority for the company through its collaboration with Nephron, and is expected to be a gamechanger for the company.
PRE-FILLED SYRINGES MARKET
- Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods.
- With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital.
Ready-To-Use – Pre-Filled Syringes:
- Types: Plastic and Type I B/S Glass
- Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy)
- End Users: Branded Pharma, CMOs, and Biologics
- Target Markets: North America
There is a growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth.
STSS announced over the summer that it had completed its acquisition of Safegard Medical’s syringe manufacturing facility in Hungary.
The manufacturing facility is located 2 hours from Budapest (160km from Budapest Airport)
- 40,000 sq. ft. factory on 250,000 sq. ft. site
- 20-year history of safety syringe manufacturing
- FDA registered since 1999
- ISO 13485 certified
- CE Mark approved products
- Injection molding and assembly expertise
- ETO on-site sterilization capacity
“The acquisition of our first manufacturing facility is an important milestone in our transformation from an R&D-focused enterprise to revenue-generating commercial operations. With the acquisition now complete, with the addition of further assembly and manufacturing capacity, our team is confident we can deliver world-class products to meet the strong and growing demand for smart safety syringes, a market forecasted to reach $14 billion globally by 2026.”
Robert Hayes, CEO of Sharps Technology
IN SUMMARY
Sharps Technology, Inc. (NASDAQ: STSS) is the newest player in the drug delivery device market to go public and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts.
- The Company recently announced a significant partnership with Nephron Pharmaceuticals with an anticipated launch into the market in early 2023.
- STSS anticipates shipping first orders of vial draw product by the beginning of 2023 and ready to fill product in mid-2023 to create initial revenue in 2023 and profits in early 2024.
- With the global shortage of syringes that comply with the World Health Organization (WHO) requirements, there is a strategic opportunity for STSS to take market share and support the healthcare industry with a better drug delivery platform.
- The combination of features and benefits for the Sharps products will save lives and eliminate the waste of critically needed medical treatments and therapies for the industry!
- There’s a key opportunity for STSS to grab a big piece of the market with its proprietary smart safety syringe technology designed to eliminate two million potentially infectious accidental needlestick injuries, as well as billions of dollars in medicine wasted with today’s inefficient syringes with their low-dead space feature.
To reiterate, the company anticipates signing its first distributor agreement during the fourth quarter of 2022, which could be at any moment!
Avalon GloboCare’s (Nasdaq: ALBT) Fusion Gene Map Technology Could Be The Greatest Investment?
Literally, this could be the best investment of the year.
Why, think about this!
Avalon is establishing a leading role in the fields of cellular immunotherapy, exosome technology (ACTEX™), and regenerative therapeutics.
Why is that a big deal?
The global cellular immunotherapy size is expected to reach USD 37.97 billion by 2030!
It is estimated to register a CAGR of 22.41% during the forecast period.
This amazing growth is driven by the growing government support for innovative therapies research, rising prevalence of cancer & development of advanced cell-based immunotherapies.
Now before we get into the top 4 reasons we like ALBT, let’s do a quick summary on the company.
Avalon GloboCare Company Summary
Company Name: Avalon GloboCare Corp.
Ticker: ALBT
Exchange: NASDAQ
Website: www.avalon-globocare.com
Avalon GloboCare Company Summary:
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
💥 RECESSION PROOF 💥
Historically, what is a great market segment to invest in during a recession, Medical!
In my opinion, The hottest vertical within The Medical market is biotech stocks.
They are safe and recession-proof.
After all, we can’t stop people from aging or from seeking treatments for a myriad of issues.
Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs.
According to Grand View Research, the global biotech industry could be worth up to $2.44 trillion by 2028.
The global cellular immunotherapy market size is expected to reach
USD 37.97 billion by 2030!
It is estimated to register a CAGR of 22.41% during the forecast period.
In THREE trading days this stock went up 40%!
Also, it created a base at $4 before it ran 40%!
GUESS WHAT?! It is at $4 again and appears to be ready to run!
Take a look at the buy ratings in #4 Section from Investing.com, Stock.ta and American Bulls!
3 TRUSTED sources saying, “BUY”
Now, let’s look mat what is driving these ratings and explosive gains, the amazing press released by ALBT below.
Jan. 03, 2023
Announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.
Dec. 14, 2022
Announced that the Company completed a private placement of shares of its Series A preferred stock with the Company’s Chairman, Daniel Lu. The gross proceeds of the offering were $4.0 million, which is in addition to the previously announced private placement of $5 million of Series A preferred stock, all of which will be used to pay a portion of the purchase price for the announced acquisition of Laboratory Services MSO, LLC.
As previously announced, the Company’s Series A preferred stock is convertible into shares of the Company’s common stock at price per share equal to the greater of $1.00 or 90% of the closing price of the Company’s common stock on the Nasdaq Stock Market on the day prior to conversion. All holders of the Series A preferred stock will be restricted from selling the shares of common stock issuable upon conversion of the Series A preferred stock for a period of 9 months and will be limited to selling no more than 10% of their shares of common stock in any calendar month.
Sept. 29, 2022
The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.
ALBT has a 52-week high of $9.40, which is MORE THAN DOUBLE compared to current levels. In fact, it would be upside of 126% if the stock climbs back there.
ALBT even has a STRONG BUY Rating From Highly Respected Investing.com!
ALBT also has a BULLISH sentiment from StockTa.com right now which can be seen HERE.
Additionally, the stock has a STAY LONG rating at AmericanBulls.com which can be seen below:
Currently ALBT boasts a relatively small trading float for a NASDAQ stock at a little over $13M.
Wall Street is still uncovering this hidden gem and with a small number of shares available for trading, a sudden demand could create a major sudden upswing in price.
Now let’s review the 4 reasons we encourage you to turn your attention to ALBT.
As a quick reminder of the 4 REASONS why you should pull up ALBT right now:
- BioTech Market Is Recession Proof
- The Chart Looks Like an “Ideal Setup”
- The Press Releases are Simply Incredible
- Buy Rating Issued from Investing.com
Source 1: https://www.grandviewresearch.com/press-release/global-cellular-immunotherapy-market
Source 2: https://www.grandviewresearch.com/industry-analysis/cellular-immunotherapy-market-
Clearmind Medicine Inc. (Nasdaq: CMND) Is Disrupting The Pharmaceutical Industry with a Revolutionary Treatment!
Clearmind Medicine CMND has consolidated from the latest amazing 252% run & indicators appear to reveal more explosive gains in the near future!
Now that it has created a base it appears ready for it’s next HUGE run, could it be 600%, 700%, 1,000%?!?!
Let’s take a quick look at the basics before digging into why CMND could be ready for it’s next big move!
Clearmind Medicine Company Summary
Company Name: Clearmind Medicine, Inc.
Ticker: CMND
Exchange: NASDAQ
Website: https://www.clearmindmedicine.com/
Clearmind Medicine Company Summary:
Clearmind Medicine Inc. (Nasdaq: CMND) is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of seven patent families.
Clearmind Medicine Inc. (Nasdaq: CMND) intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind’s flagship treatments are focused on Alcohol Use Disorder(AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.
Clearmind Medicine Inc. Scores Milestone Patent
Dec 27, 2022
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) has taken a giant step forward in its mission to deliver a first-to-market psychedelic-based treatment targeting Alcohol Use Disorder (AUD). Last Wednesday, CMND announced being granted a patent from the United States Patent and Trademark Office (USPTO) to use its proprietary MEAI as an alcoholic beverage substitute. This allowance strengthens an already robust IP portfolio by adding to similar patents earned for its MEAI-based alcohol substitute in Europe and India.
The full article can be found HERE
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
January 3rd, 2023
Driving that proposition is Clearmind Medicine nearing its goal of delivering a first-to-market psychedelic-based treatment to market, with its lead candidate, MEAI, targeting a $395BN alcohol-substitute product market.
“In pre-clinical trials, showed an ability to mitigate AUD Alcohol Use Disorder: a condition that encourages a vicious cycle of binge drinking by circumventing specific neural pathways that lead to sensible behavioral decisions. “
The full article can be found HERE
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For Alcohol Use Disorder
Dec 29, 2022
Thanks to a series of milestones reached, patents earned, and valuable partnerships, the company’s lead candidate, MEAI, may soon become the first-to-market psychedelic-based treatment targeting Alcohol Use Disorder (AUD). As an alcohol-substitute product, MEAI positions Clearmind to target a more than $395 million alcohol-substitute market opportunity and, more importantly, provide a product that could save millions of lives each year.
The full article can be found HERE
There is a massive market potential for Clearmind Medicine Inc. (Nasdaq: CMND). The company focuses on a huge untapped market with yearly economic impact costing the U.S. over $249 billion.(1)
Clearmind Medicine Inc. (Nasdaq: CMND) currently has 8 patents granted with 15 patent applications pending.(1) A patent can be an economic catalyst to pharmaceutical companies who push to research new and beneficial drugs on the premise that they will be able to reap rewards by way of profits.(2)
According to a national survey, 14.1 million adults ages 18 and older (5.6 percent of this age group) had AUD in 2019. (3)
Among youth, an estimated 414,000 adolescents ages 12–17 (1.7 percent of this age group) had AUD during this timeframe.(3)
What Increases the Risk for AUD? A person’s risk for developing AUD depends, in part, on how much, how often, and how quickly they consume alcohol. (3)
Alcohol misuse, which includes binge drinking and heavy alcohol use, over time increases the risk of AUD.(3)
Other factors also increase the risk of AUD, such as:
- Drinking at an early age. A recent national survey found that among people ages 26 and older, those who began drinking before age 15 were more than 5 times as likely to report having AUD in the past year as those who waited until age 21 or later to begin drinking. The risk for females in this group is higher than that of males. (3)
- Genetics and family history of alcohol problems. Genetics play a role, with heritability approximately 60 percent; however, like other chronic health conditions, AUD risk is influenced by the interplay between a person’s genes and their environment. Parents’ drinking patterns may also influence the likelihood that a child will one day develop AUD.(3)
- Mental health conditions and a history of trauma. A wide range of psychiatric conditions—including depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder—are comorbid with AUD and are associated with an increased risk of AUD. People with a history of childhood trauma are also vulnerable to AUD.(3)
Breaking the Cycle
Clearmind Medicine Inc. (Nasdaq: CMND) believes that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol,by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior.”(6)
Non-Addictive
Anecdotal reports and pre-clinical in-vivo results indicate on the self-limiting property of MEAI—unlike traditional treatments.(6)
Expansive Potential
The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.(6)
Successful preclinical results in MEAI treatment for alcohol consumption.(6)
Clearmind Medical is advancing its proprietary CMND-100, 5-methoxy-2-aminoindane-based treatment (MEAI), intending to provide relief to millions worldwide by using psychedelics to treat Alcohol Use Disorder (AUD).
The market potential from an approved CMND therapeutic can be enormous, replacing drugs and treatments that are sometimes more debilitating than the condition itself.
More importantly, CMND’s approach could mitigate patient resistance to treatment, opening the door to potentially billions in long-term revenues and saving thousands of lives per year.
Biotech and Pharmaceutical stocks can offer tremendous upside potential when positive news is announced from Phase 1, Phase 2, and Phase 3 trials. Clearmind Medicine Inc. (Nasdaq: CMND) recently announced the initiation of a program to address its upcoming clinical trial.(4)
Clearmind Medicine Inc. recently announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100.(4)
The produced batches will be used in the Company’s upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Following MEAI’s synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company’s pre- clinical studies designed to evaluate the safety of its innovative compound.
“Clearmind continues its progress toward FIH clinical trials,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.
“This milestone joins other achievements we’ve made in a relatively short period. Non-clinical data generated to date, demonstrate that our MEAI- based treatment has the potential to treat broad range of addictions and binge behaviors such as AUD.”(4)
“Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use,” she added. (4)
“Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition.”(4)
The Company previously announced that it completed a highly constructive Pre-Investigational New Drug Application (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of CMND-100.
Clearmind Medicine Inc. (Nasdaq: CMND) has less than 1.2M shares available in its public float according to Finviz.(5) Low float stocks have the potential to present significant price swings if active market participants take notice.
Short squeeze?
If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. Low float stocks can be some of the most volatile stocks in the market.
Clearmind Medicine CMND has consolidated from the latest amazing 252% run & indicators appear to reveal more explosive gains in the near future! Let’s review the 4 reasons you should put it on you watchlist NOW.
As a quick reminder of the 4 REASONS why you should pull up KAVL right now:
- Incredible Press Releases announcing their US Patent!
- Untapped Market Worth $249BN
- Clinical Trials on the horizon that could be worth Bill-ions
- Extremely Low Float – 1.2M shares is stupid LOW!
Source 1: https://www.clearmindmedicine.com/investors
Source 2: https://www.mckendree.edu/academics/scholars/issue11/bodem.htm
Source 3: https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder
Source 4: https://finance.yahoo.com/news/clearmind-announces-initiation-cmnd-100-134500937.html
Source 5: https://finviz.com/quote.ashx?t=CMND&p=d
Source 6: https://www.clearmindmedicine.com/investors